Lymphoma

Lymphoma

We’re here for you. Call us at 844-346-7222 or

find a clinical trial

If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at (201) 518-3587, or email us at email.

60 Clinical Trials
Lymphoma NA Active
nct/study# NCT04981795 / MOR208C414

Prospective Multicenter Observational Study Of Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma Starting Second- Or Third-Line Therapy And Not Receiving Autologous Stem Cell Transplant (REAL-MIND)

Learn More
Lymphoma N/A Active
nct/study# NCT04982471 / NDS-DLBCL-003

Connect® Lymphoma Disease Registry: A Us-Based Prospective Observational Cohort Study

Learn More
Lymphoma Phase I/II Accepting Patients
nct/study# NCT03033914 / MSK16-1536

Phase I/II Of Nivolumab And A(B)VD In The Front-Line Setting For High Risk Hodgkin Lymphoma

Learn More
Lymphoma Phase II Accepting Patients
nct/study# NCT03233347 / LY-1601

A Phase II Trial Of PET-Directed Therapy Using AVD (Doxorubicin, Vinblastine, And Dacarbazine) Plus Brentuximab Vedotin Induction Chemotherapy, With Or Without Brentuximab Vedotin Plus Nivolumab, Followed By Nivolumab Consolidation For Patients With Previously Untreated Non-Bulky Limited Stage Hodgkin Lymphoma

Learn More
Lymphoma NA Accepting Patients
nct/study# NCT03711604 / RP6530-1803

An Open Label, Compassionate Use Study Of Tenalisib (RP6530) In Patients Currently Receiving Treatment On Tenalisib Trials In Hematological Malignancies

Learn More
Lymphoma Phase I/II Accepting Patients
nct/study# NCT02628405 / RU051417I

Phase I/II, Open-Label Study Of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) With Lenalidomide-R-ICE (R2-ICE) In Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Learn More

We are here for you

For more information or to schedule an appointment, call (844) 346-7222. You can also schedule an appointment by calling the RCCA location nearest you.

Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.